Protagonist Therapeutics (PTGX) Receivables (2015 - 2021)

Protagonist Therapeutics has disclosed Receivables across 7 years of filings, most recently posting $1.6 million for Q4 2021.

• Receivables for Q4 2021 came in at $1.6 million, down 35.45% year-over-year; the trailing twelve-month figure through Dec 2021 was $1.6 million (down 35.45% YoY), and the FY2021 annual result was $1.6 million, down 35.45% from the prior year.
• Receivables came in at $1.6 million for Q4 2021 at Protagonist Therapeutics, down from $2.6 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $7.1 million in Q2 2021 to a low of $19000.0 in Q2 2017.
• The 5-year median for Receivables is $2.8 million (2018), against an average of $3.1 million.
• Across the five-year window, Receivables slumped 91.52% in 2017 and soared 30684.21% in 2018, its largest moves.
• Protagonist Therapeutics' Receivables stood at $1.9 million in 2017, then surged by 52.29% to $2.9 million in 2018, then surged by 119.17% to $6.3 million in 2019, then sank by 61.22% to $2.4 million in 2020, then sank by 35.45% to $1.6 million in 2021.
• The last three Receivables figures came in at $1.6 million (Q4 2021), $2.6 million (Q3 2021), and $7.1 million (Q2 2021), per Business Quant data.